Gel-One is administered as a single intra-articular injection directly into the knee joint by a qualified healthcare professional, typically an orthopedic surgeon, rheumatologist, or sports medicine physician. It is not designed for self-administration.
- Preparation: Before the injection, the healthcare provider will prepare the injection site using strict aseptic (sterile) technique to prevent infection. If there is excess fluid (effusion) in the knee joint, it is usually aspirated (removed) using a separate syringe before injecting Gel-One.
- Administration: The entire contents of the pre-filled 3 mL syringe (containing 30 mg of cross-linked hyaluronate) are injected into the intra-articular space of the knee. If both knees require treatment, a separate syringe of Gel-One is used for each knee.
- Post-Injection Care:
- Patients are usually advised to avoid strenuous activities, heavy lifting, high-impact sports (like jogging, tennis), or prolonged weight-bearing activities (standing for more than one hour) for at least 48 hours after the injection. This allows the Gel-One to settle and the knee to recover.
- Some temporary pain, swelling, or warmth at the injection site is common after the procedure. Applying ice packs and using simple analgesics (e.g., acetaminophen) as advised by the doctor can help manage these symptoms.
- Treatment Course: Unlike some other viscosupplements that require a series of injections, Gel-One is designed as a single-injection treatment. The safety and effectiveness of repeat treatment cycles of Gel-One have not been formally established, so a single injection is typically the standard course.
Gel-One works by supplementing the degraded or depleted natural hyaluronic acid in the osteoarthritic knee joint, a process known as viscosupplementation.
- Restoring Viscoelasticity: In a healthy joint, synovial fluid, rich in high molecular weight hyaluronic acid, acts as a lubricant and a shock absorber, allowing smooth movement of the joint surfaces and protecting the cartilage. In osteoarthritis, the synovial fluid loses its viscoelastic properties. By injecting exogenous, cross-linked hyaluronate (Gel-One), the viscoelasticity of the synovial fluid is enhanced, helping to restore its natural lubricating and shock-absorbing functions.
- Lubrication: The increased lubrication reduces friction between the articulating bone surfaces covered by cartilage, which can significantly lessen pain during movement.
- Shock Absorption: The improved shock-absorbing capacity helps to protect the remaining cartilage from further wear and tear during weight-bearing activities.
- Anti-Inflammatory Effects: Hyaluronic acid may also have direct anti-inflammatory properties, reducing the inflammatory processes within the joint that contribute to pain and degradation.
- Endogenous Hyaluronate Production: There is also a theory that the presence of exogenous hyaluronic acid might stimulate the body’s own synovial cells to produce more and higher quality endogenous hyaluronic acid, thereby further contributing to the long-term benefits.
By restoring these critical functions, Gel-One aims to alleviate pain, improve joint mobility, and delay the progression of symptoms in patients with knee osteoarthritis.
While generally well-tolerated, Gel-One injections can cause side effects, most of which are localized to the injection site.
- Common Local Side Effects (usually mild and temporary):
- Injection site pain: Discomfort or pain at the site where the needle was inserted.
- Joint swelling (knee): Swelling around the knee, often mild to moderate.
- Joint effusion (fluid buildup in the knee): Accumulation of excess fluid within the joint.
- Joint stiffness (knee).
- Warmth, redness, or bruising at the injection site.
- Less Common/Rare Side Effects (may require medical attention):
- “Pseudo-sepsis” reaction: A rare, severe inflammatory reaction mimicking an infection, characterized by marked swelling, redness, warmth, and severe pain in the injected joint. It is not a true infection but requires immediate medical evaluation to rule out actual infection and manage symptoms.
- Allergic reactions: Though rare, systemic allergic reactions (e.g., hives, rash, itching, swelling of the face/tongue/throat, difficulty breathing) are possible.
- Infection: As with any intra-articular injection, there is a small risk of joint infection, which is a serious complication requiring immediate medical treatment. Signs include severe pain, swelling, redness, fever, and chills.
- Changes in gait (walking pattern).
- General body aches, headache, dizziness, nausea, or sore throat: These are less common and usually mild.
Any persistent or severe side effects, or signs of infection, should be reported to the healthcare provider immediately.
Several important warnings and precautions are associated with Gel-One to ensure safe and appropriate use.
- Hypersensitivity/Allergies: Gel-One is contraindicated in patients with known hypersensitivity (allergy) to Gel-One, hyaluronate preparations, or products from birds (e.g., feathers, eggs, poultry, cinnamon), as the hyaluronate can be derived from avian sources.
- Infection/Skin Conditions at Injection Site: Do not inject Gel-One into the knees of patients with skin diseases or infections in the area of the injection site, as this significantly increases the risk of joint infection.
- Intravascular Injection: Gel-One must not be injected intravascularly (into a blood vessel) or extra-articularly (outside the joint space) or into the synovial tissue and capsule. Strict aseptic technique is crucial.
- Joint Effusion: If significant joint effusion (excess fluid) is present, it should be removed (aspirated) before injecting Gel-One to ensure proper distribution and effectiveness of the product.
- No Established Safety in Certain Populations: The safety and effectiveness of Gel-One have not been established in:
- Severely inflamed knee joints.
- Joints other than the knee.
- Concomitant use with other intra-articular injectables.
- Repeat treatment cycles.
- Pregnant or nursing women.
- Children or individuals under 21 years of age.
- Post-Injection Activity: Patients must be advised to avoid strenuous or prolonged weight-bearing activities for at least 48 hours following the injection to prevent complications and allow the product to settle.
- Sterility: The pre-filled syringe is for single use only. The contents must be used immediately once the package is opened, and any unused portion discarded. Do not use if the blister package is opened or damaged, or if there are cracks in the syringe.
As an intra-articular injection, Gel-One has a low risk of systemic drug interactions because it is not significantly absorbed into the bloodstream. The interactions are primarily localized to the joint or related to the administration procedure.
- Quaternary Ammonium Salts: Do not concomitantly use disinfectants containing quaternary ammonium salts (e.g., benzalkonium chloride) for skin preparation, as hyaluronic acid can precipitate in their presence, potentially compromising the product’s integrity or effectiveness.
- Other Intra-Articular Injections: The safety and effectiveness of using Gel-One concurrently with other intra-articular injectables (e.g., corticosteroids, other viscosupplements) have not been established. It’s generally recommended to avoid co-administration or to space out injections if multiple substances are used.
- Local Anesthetics: A local anesthetic (e.g., lidocaine) may be injected subcutaneously prior to the Gel-One injection to minimize pain during the procedure. This is a common practice and is not considered an adverse interaction.
- Systemic Medications: There are no known direct interactions between Gel-One and systemic medications (oral drugs, other injections) as Gel-One remains largely localized within the joint space and is metabolized there.
Always inform your healthcare provider about all medications, supplements, and other treatments you are receiving to ensure proper management and avoid any potential complications.
The dosage guidelines for Gel-One are straightforward due to its single-injection protocol. It is always administered by a trained healthcare professional.
- Standard Dosage: A single 3 mL syringe of Gel-One, containing 30 mg of cross-linked hyaluronate, is injected directly into the intra-articular space of the affected knee.
- Administration Frequency: Gel-One is designed as a single intra-articular injection. Unlike some other viscosupplements that require a series of weekly injections, Gel-One provides its full intended effect with just one administration.
- Bilateral Knees: If both knees are affected by osteoarthritis and deemed suitable for treatment, a separate, sterile syringe of Gel-One must be used for each knee.
- Preparation Prior to Injection: As described in the “How to Use” section, any existing joint effusion should be aspirated before the injection of Gel-One.
- No Repeat Cycles Established: The safety and effectiveness of repeat treatment cycles of Gel-One have not been formally established. Therefore, re-injection schedules are not defined in the same way as for multi-injection viscosupplements. If pain recurs after the initial treatment, the healthcare provider will reassess the patient’s condition and consider other treatment options.
Gel-One (cross-linked hyaluronate) for intra-articular injection is a prescription-only medical device. It is not available over-the-counter.
- Licensed Healthcare Professional Administration: Due to its nature as an injectable procedure and the requirement for sterile technique and anatomical knowledge, Gel-One must be administered by a licensed healthcare professional (e.g., orthopedic surgeon, rheumatologist, sports medicine physician).
- Medical Evaluation: A thorough medical evaluation, including diagnosis of knee osteoarthritis and assessment of previous treatment failures, is necessary before a prescription for Gel-One is issued. The decision to use Gel-One is made by the physician based on the patient’s clinical presentation and individual needs.
- Controlled Environment: The injection procedure typically takes place in a clinical setting (doctor’s office, clinic, or hospital) equipped for sterile injections, not for self-administration at home.
- Regulatory Classification: While it’s a biologic substance, hyaluronic acid-based injections are often regulated as medical devices rather than drugs in some regions, but they still require a prescription due to their invasive nature and the need for professional administration.
Patients should never attempt to obtain or administer Gel-One themselves, and its use should always be part of a comprehensive treatment plan supervised by a qualified physician.
